Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 multicenter, randomized, double-blind, parallel group, placebo controlled trial to evaluate the efficacy of TAK-390MR (30 mg QD) [dexlansoprazole] compared to placebo on relief of nocturnal heartburn in subjects with symptomatic gastroesophageal reflux disease (GERD).

Next Previous
Trial Profile

A phase 3 multicenter, randomized, double-blind, parallel group, placebo controlled trial to evaluate the efficacy of TAK-390MR (30 mg QD) [dexlansoprazole] compared to placebo on relief of nocturnal heartburn in subjects with symptomatic gastroesophageal reflux disease (GERD).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexlansoprazole (Primary)
  • Indications Gastro-oesophageal reflux; Heartburn
  • Focus Therapeutic Use
  • Sponsors Takeda Global Research and Development Center; TAP Pharmaceutical Products

Most Recent Events

  • 28 Oct 2009 Results presented at the 74th Annual Scientific Meeting of the American College of Gastroenterology.
  • 26 Oct 2009 New results data presented at 74th Annual Scientific Meeting of the American College of Gastroenterology (ACG 2009), according to a Takeda pharmaceuticals media release.
  • 24 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top